Approval of LAAM (levomethadyl acetate, Orlaam®) as 2 to 3 times per week treatment for opioid dependence.
Evaluation of long-term methadone or LAAM therapy in reducing illicit opioid drug use in many patients.
Evaluation of buprenorphine and other partial agonist compounds as safer replacements for methadone treatment.
Evaluation of catalytic antibodies for degrading or inactivating cocaine.
Expanded evaluation of selective dopamine, serotonin, and opioid agonists and antagonists for cocaine addiction.
Expanded examination of the concept of agonist replacement strategies and specific medications.
Naltrexone (ReVia™) approved for treatment of alcoholism in the United States.
Acamprosate (Aotal®) approved for treatment of alcoholism in Europe, and gamma-hydroxybutyrate approved for treatment of alcoholism in Italy.
Expanded research into use of serotonin reuptake inhibitors, opioid antagonists, serotonin 5-HT3 receptor antagonists, drug combinations, and other pharmacological treatments.